APL 102
Alternative Names: APL-102; CBT 102Latest Information Update: 28 May 2023
At a glance
- Originator CBT Pharmaceuticals
- Developer Apollomics
- Class Antineoplastics; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Colony stimulating factor receptor antagonists; Discoidin domain receptor 1 antagonists; Mitogen-activated protein kinase inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
- 10 Aug 2021 Phase-I clinical trials in Solid tumours in China (PO)
- 11 Nov 2020 Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approves IND application for a phase I trial in Solid tumours in China